

Helicobacter Pylori: Adult

Gastrointestinal

Clinical Decision Tools for RNs with Additional Authorized Practice [RN(AAP)s]

Effective Date: June 9, 2022

Background

Helicobacter pylori (*H. pylori*) is the most prevalent chronic bacterial infection worldwide (Crowe, 2019a; Crowe, Feldman & Grover, 2019; Thomas, 2019) and plays a key role in the pathogenesis of peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma (Crowe, 2019a). *H. pylori* causes ulceration (predominantly duodenal) of the mucous membrane of the upper digestive tract (Crowe et al., 2019; Thomas, 2019). Most infections of *H. pylori* are acquired before the age of five (Crowe, 2019a) with 30-50% of the world's population colonized with this pathogen (Thomas, 2019). Studies suggest that *H. pylori* is most readily cultured from emesis or diarrhea suggesting that transmission occurs during periods of illness (Crowe et al., 2019). In absence of such illness, children who regularly swim in rivers, streams, pools, drink stream water or eat uncooked vegetables are more likely to be infected (Crowe et al., 2019).

Immediate Consultation Requirements

The RN(AAP) should seek immediate consultation from a physician/NP when any of the following circumstances exist:

- pain radiates to the back, neck, jaw, left arm or shoulder;
- protracted vomiting;
- active gastrointestinal bleeding (black stools, hematemesis);
- abdominal mass;
- weight loss (unintentional);
- dysphagia; and/or
- clients with alcohol use disorder related to potential disulfiram reaction with use of metronidazole (Interprofessional Advisory Group [IPAG], personal communication, October 20, 2019).

Predisposing and Risk Factors

Predisposing and risk factor for *H. pylori* is related to socioeconomic status and poor living conditions in early life (Crowe et al., 2019). Density of housing, overcrowding, increased number of siblings, sharing a bed, ingesting unwashed and/or uncooked contaminated foods, unreliable supply of clean water, and close contact with individuals with *H. pylori* have all been linked to a higher rate of infection (Crowe et al., 2019; Thomas, 2019).

Health History and Physical Exam

Subjective Findings

The circumstances of the presenting complaint should be determined. These include:

- epigastric tenderness;
- nausea and vomiting;
- epigastric pain worse when stomach is empty (described as aching or burning);
- indigestion, bloating, and fullness;
- flatulence;
- hematemesis;
- loss of appetite/weight loss;
- pain at nighttime; and/or
- melena stools (Crowe et al., 2019; Thomas, 2019).

Objective Findings

In uncomplicated *H. pylori* clinical findings are few and nonspecific but may include:

- halitosis,
- epigastric/abdominal tenderness on palpation,
- stool positive for occult blood, and/or
- frequent flatus (Crowe et al., 2019; Thomas, 2019).

Differential Diagnosis

The following should be considered as part of the differential diagnosis:

- nonsteroidal anti-inflammatory drug induced peptic ulcer disease,
- esophagitis,
- functional dyspepsia,
- gastritis,
- gastroenteritis,
- gastroesophageal reflux disease,
- celiac disease,
- cholangitis,

- cholecystitis,
- cholelithiasis,
- esophageal perforation,
- inflammatory bowel disease
- irritable bowel syndrome,
- abdominal aortic aneurysm,
- acute coronary syndrome,
- Barrett's esophagus,
- gastric cancer,
- viral hepatitis, and/or
- Zollinger-Ellison syndrome (Crowe et al., 2019; Thomas, 2019).

Making the Diagnosis

Presumptive diagnosis can be made based on history and physical findings. Definite diagnosis is confirmed with laboratory testing (Thomas, 2019).

Investigations and Diagnostic Tests

Any one of the following tests can be used to diagnose *H. pylori* and should only be used in clients suspected of having the infection and when treatment is planned (RxFiles Academic Detailing Program, 2021).

The stool antigen test (SAT) is preferred as it yields fewer false positive results and can be performed in an outpatient setting. To avoid false negative results, the client must be advised they cannot have taken antibiotics for a minimum of 28 days, must hold proton-pump inhibitors and bismuth preparations (i.e., Pepto Bismol®) for a minimum of 14 days; and hold histamine H2-receptor antagonists (i.e., famotidine) and antacids (i.e., Diovol®) for a minimum of one day. The stool sample must not come in contact with water or urine and should be taken to the laboratory within 18 hours of collection and refrigerated until it is brought to the laboratory (RxFiles Academic Detailing Program, 2021).

The urea breath test (UBT) has a 90% sensitivity but requires referral to tertiary care facility. Preparation for this test varies and will be provided by the department conducting the test (RxFiles Academic Detailing Program, 2021).

The serological antibody test can also be performed in an outpatient setting but it has high rates of false positive results, especially in younger clients (Crowe, 2019b; Thomas, 2019). The test cannot differentiate active disease from previous exposure. If positive confirm findings with a SAT or UBT (Rx Files Academic Detailing Program, 2021).

Biopsy with histological examination requires a referral to a gastroenterologist or general surgeon for gastroscopy (Crowe, 2019b; Thomas, 2019).

Management and Interventions

Goals of Treatment

The primary goals of immediate treatment are to relieve symptoms, treat the infection, prevent complications, and prevent transmission (Thomas, 2019).

Non-Pharmacological Interventions

The RN(AAP) should recommend, as appropriate, non-pharmacological options including smoking cessation and reduction or cessation of alcohol ingestion (Thomas, 2019).

Pharmacological Interventions

The pharmacological interventions recommended for the treatment of *H. pylori* are in accordance with *RxFiles: Drug comparison charts* (RxFiles Academic Detailing Program, 2021) and *Anti-Infective Guidelines for Community-acquired Infections* (Anti- Infective Review Panel, 2019).

H. Pylori Treatment Regimens

Management of *H. pylori* includes a combination of a proton-pump inhibitor, antibiotics and bismuth subsalicylate in some of the regimes. Avoid bismuth subsalicylate if client has severe renal dysfunction (CrCl < 30 mL/min).

	Drug	Dose	Route	Frequency	Duration
Adult (option one)					
	Esomeprazole	40 mg	p.o.	b.i.d.	14 days
OR	Lansoprazole	30 mg	p.o.	b.i.d.	14 days
OR	Omeprazole	20 mg	p.o.	b.i.d.	14 days
OR	Pantoprazole	40 mg	p.o.	b.i.d.	14 days
OR	RABEprazole	20 mg	p.o.	b.i.d.	14 days
PLUS	Metronidazole	500 mg	p.o.	b.i.d.	14 days
PLUS	Clarithromycin	500 mg	p.o.	b.i.d.	14 days
Adult (option two)					
	Esomeprazole	40 mg	p.o.	b.i.d.	14 days

	Drug	Dose	Route	Frequency	Duration
OR	Lansoprazole	30 mg	p.o.	b.i.d.	14 days
OR	Omeprazole	20 mg	p.o.	b.i.d.	14 days
OR	Pantoprazole	40 mg	p.o.	b.i.d.	14 days
OR	RABEprazole	20 mg	p.o.	b.i.d.	14 days
PLUS	Bismuth subsalicylate (Pepto Bismol)	2 caplets	p.o.	q.i.d.	14 days
PLUS	Metronidazole	500 mg	p.o.	t.i.d. or q.i.d.	14 days
PLUS	Tetracycline	500 mg	p.o.	q.i.d. ac meals	14 days
OR	Amoxicillin	1 gram	p.o.	b.i.d.	14 days

Client and Caregiver Education

The RN(AAP) provides client and caregiver education as follows:

- Counsel about appropriate use of medications (dose, frequency, application, compliance, etc.).
- Advise that it is imperative to complete the entire course of therapy to ensure eradication of *H. pylori*.
- Recommend alternatives to nonsteroidal anti-inflammatory drugs, smoking cessation, and minimizing the use of alcohol (Anti-Infective Review Panel, 2019).

Monitoring and Follow-Up

The RN(AAP) should:

- Advise follow-up after therapy completed or if symptoms progress despite therapy or if symptoms fail to respond to therapy.
- Confirming the eradication of *H. pylori* is suggested for those with complicated bleeding ulcers. Follow-up testing should be done no earlier than one month after therapy is completed. The SAT is the diagnostic test of choice as antibodies may persist for months after eradications in serology (Anti-Infective Review Panel, 2019).

Complications

H. pylori may be associated with the development of peptic ulcer disease and gastric cancer (Crowe et al., 2019; Thomas, 2019).

Referral

Refer to a physician/NP if client presentation is consistent with those identified in the *Immediate Consultation Requirements* section, where there is diagnostic uncertainty, or who has not responded to treatment (IPAG, personal communication, October 20, 2019).

References

Anti-infective Review Panel. (2019). *Anti-infective guidelines for community-acquired infections*. MUMS Guideline Clearinghouse.

Crowe, S.E. (2019a). *Bacteriology and epidemiology of Helicobacter pylori infection*. https://www.uptodate.com/contents/bacteriology-and-epidemiology-of-helicobacter-pylori-infection?search=bacteriology%20and%20epidemiology%20of%20Helicobacter%20pylori%20infection&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

Crowe, S.E. (2019b). *Indications and diagnostic tests for Helicobacter pylori infection*. https://www.uptodate.com/contents/indications-and-diagnostic-tests-for-helicobacter-pylori-infection?search=indications%20and%20diagnostic%20tests%20for%20helicobacter%20pylori%20infection&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

Crowe, S.E., Feldman, M., & Grover, S. (2019). *Pathophysiology of and immune response to Helicobacter pylori infection*. https://www.uptodate.com/contents/pathophysiology-of-and-immune-response-to-helicobacter-pylori-infection?search=pathophysiology%20of%20and%20immune%20response%20to%20Helicobacter%20pylori%20infection&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

<http://www.rxfiles.ca/rxfiles/uploads/documents/ABX-Newsletter-2016-COMplete.pdf><http://www.rxfiles.ca/rxfiles/uploads/documents/ABX-Newsletter-2016-COMplete.pdf>https://mail.myaccess.ca/service/home/~/CHT-Hpylori.pdf?auth=co&loc=en_US&id=132986&part=2https://mail.myaccess.ca/service/home/~/CHT-Hpylori.pdf?auth=co&loc=en_US&id=132986&part=2 Rx Files Academic Detailing Program. (2021). *RxFiles: Drug comparison charts*. (13th ed.). Saskatoon Health Region.

Thomas, D. J. (2019). Gastric and intestinal disorders. In L. Dunphy, J. Winland-Brown, B. Porter, & D. Thomas (Eds.), *Primary care: The art and science of advanced practice nursing – an interprofessional approach* (5th ed., pp. 565–602). F.A. Davis.

NOTICE OF INTENDED USE OF THIS CLINICAL DECISION TOOL

This CRNS Clinical Decision Tool (CDT) exists solely for use in Saskatchewan by an RN with additional authorized practice as granted by the CRNS. The CDT is current as of the date of its publication and updated every three years or as needed. A member must notify the CRNS if there has been a change in best practice regarding the CDT. This CDT does not relieve the RN with additional practice qualifications from exercising sound professional RN judgment and responsibility to deliver safe, competent, ethical and culturally appropriate RN services. The RN must consult a physician/NP when clients' needs necessitate deviation from the CDT. While the CRNS has made every effort to ensure the CDT provides accurate and expert information and guidance, it is impossible to predict the circumstances in which it may be used. Accordingly, to the extent permitted by law, the CRNS shall not be held liable to any person or entity with respect to any loss or damage caused by what is contained or left out of this CDT.

CRNS © This CDT is to be reproduced only with the authorization of the CRNS.